BSBrianna M. Sullivan

Brianna M. Sullivan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brianna M. Sullivan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a Culturally Adapted Smartphone Smoking Cessation App (DecideACT) for Hispanic Adults: User-Centered Mixed Methods Study (Preprint)

    by Margarita Santiago-Torres, Ana Paula Cupertino, Brianna M. Sullivan, Kristin E. Mull, Arlette Chávez-Iñiguez, Oscar Chavez, Victoria Chavez-Uceda, Sofia Cobos, Camille A. Fogel, Soo Bin Hwang, et al.

    BACKGROUND In the United States (U.S.), Hispanic adults who smoke face disparities in receiving advice to quit and accessing evidence-based, culturally and linguistically relevant smoking cessation treatment. These disparities reflect inequitable access to support rather than a lower capacity to quit successfully. OBJECTIVE This study aimed to evaluate the cultural relevance and acceptability of a culturally and linguistically adapted version of iCanQuit, an evidence-based smartphone app that uses Acceptance and Commitment Therapy (ACT) to support smoking cessation, for Hispanic adults. METHODS A community-engaged, user-experience (UX) testing multistep adaptation approach was used. Step 1 involved selecting theory-based frameworks to guide the process; identifying relevant smoking cessation themes among Hispanic individuals through a scientific literature review; and collaborating with a Community Advisory Board (CAB) composed of Hispanic individuals of diverse age groups, gender, occupations, and Hispanic national-origin groups. Step 2 entailed developing an app prototype. Step 3 evaluated the cultural relevance and acceptability of the app through UX testing across six consecutive days of app usage followed by one-on-one interviews conducted remotely. English- and Spanish-speaking Hispanic adults who wanted to quit smoking were recruited nationwide via social media. Recommendations for improvement were identified using inductive qualitative content analysis. RESULTS Prototype development included redesigning imagery; emphasizing culturally salient values such as family unity, warm and trusting relationships, and resilience; expanding avatar testimonials reflecting relevant stress-related barriers to cessation; and creating interactive, avatar-led smoke-free challenges to help users build confidence toward longer periods without smoking. Through a consensus-based process, CAB members selected the name DecideACT, emphasizing bilingual appeal and alignment with ACT principles. They also co-created the app's guide avatar, Sofia, shaping her into a culturally relevant, trustworthy, and relatable source of support. UX testing included eighteen Hispanic adults aged 24 to 59 years (55.6% women) who reported smoking 1-20 cigarettes daily, on avarage. Reported Hispanic identities included Chile, Colombia, Cuba, Mexico, Peru, Puerto Rico, Spain, and Venezuela. Six participants completed UX testing in Spanish. All 18 participants reported positive experiences. Across days, 28% of ratings were excellent, 35% very good, 35% good, and 2% fair. Participants generally perceived the app as culturally relevant, with 70% of ratings as extremely (35%) or moderately (35%) relevant, and 29% as somewhat relevant. Participants found Sofia relatable and likable (15/18) and responded positively to avatars and their stories (15/18). Key recommendations included expanding avatar narratives, increasing reminders visibility, making push notifications more engaging, and improving navigation support. This feedback was integrated into subsequent revisions of the final DecideACT app. CONCLUSIONS DecideACT is an ACT-based, bilingual, smoking cessation app culturally adapted for Hispanic adults. Findings support its relevance and acceptability and provide a foundation for subsequent evaluation of feasibility and cessation outcomes. CLINICALTRIAL ClinicalTrials.gov Identifier, NCT06811038; https://clinicaltrials.gov/study/NCT06811038

  • Open Access

    A Culturally Adapted Smoking Cessation App (IndigeQuit) for American Indian and Alaska Native Adults: Protocol for a Randomized Clinical Trial

    by Jonathan B Bricker, Margarita Santiago-Torres, Brianna M Sullivan, Kristin E Mull, Hershel W Clark, Chase Kornacki, Trivia Afraid Of Lightning-Craddock, Dean S Seneca, Crystal M Stanford, Sierra L Wilcox, et al.

    Background: Due to limited access to evidence-based cessation support, American Indian and Alaska Native (AI/AN) adults are half as likely to quit commercial cigarette smoking as other racial and ethnic groups. Geographical barriers, underfunded health systems, and limited integration of cessation services into routine care have reduced access to effective treatment in AI/AN communities. These challenges are compounded by a lack of culturally relevant interventions tailored to AI/AN adults. Thus, there is an urgent need for accessible, scalable, and culturally relevant interventions. Objective: Here, we describe the protocol for a randomized clinical trial (RCT) testing the efficacy of a culturally adapted smoking cessation app (IndigeQuit) developed specifically to help AI/AN adults quit smoking commercial cigarettes compared to a standard, nontailored app (QuitGuide). Methods: To improve the relevance and acceptability of cessation support to AI/AN adults, IndigeQuit was developed through a cultural adaptation of iCanQuit, an evidence-based smartphone app grounded in acceptance and commitment therapy that teaches skills for accepting cravings to smoke. The cultural adaptation used a user-centered, community-based participatory research mixed methods approach in collaboration with a community advisory board (CAB) comprising AI/AN individuals. Cultural adaptations included the use of Native imagery; stories featuring AI/AN adults and elders emphasizing culture, spirituality, family, and community; and the important distinction between ceremonial and commercial tobacco. A total of 776 AI/AN adults who smoke and want to quit are being recruited nationwide and randomized to receive IndigeQuit or QuitGuide for 12 months. The primary aim of the RCT is to determine the efficacy of IndigeQuit compared with QuitGuide for 30-day abstinence at 12 months. Secondary aims include abstinence at earlier time points, identifying mediators and moderators of treatment effects, and assessing engagement and satisfaction. Qualitative interviews with IndigeQuit participants and CAB members will inform the development of a subsequent guide to support the broad dissemination of IndigeQuit nationwide. Results: The National Cancer Institute funded this study in 2024 (grant R01 CA284687), with the grant awarded to the principal investigator, JBB. As of August 2026, a total of 590 AI/AN adults had been enrolled in the trial. Data collection started in July 2025 and is expected to be completed by November 2028. Conclusions: The IndigeQuit app was designed to deliver evidence-based smoking cessation treatment that is culturally adapted to AI/AN communities and grounded in acceptance and commitment therapy. If effective, this intervention could offer a more scalable and culturally relevant treatment to AI/AN communities nationwide, helping to reduce smoking-related health inequities. Trial Registration: ClinicalTrials.gov NCT06145763; https://clinicaltrials.gov/study/NCT06145763 International Registered Report Identifier (IRRID): DERR1-10.2196/102675

  • Open Access

    IndigeQuit: Protocol for a Randomized Clinical Trial of a Culturally Adapted Smoking Cessation App for American Indian and Alaska Native Adults (Preprint)

    by Jonathan B Bricker, Margarita Santiago-Torres, Brianna M. Sullivan, Kristin E. Mull, Hershel W. Clark, Chase Kornacki, Trivia Afraid Of Lightning-Craddock, Dean S. Seneca, Crystal M. Stanford, Sierra L. Wilcox, et al.

    BACKGROUND Gaps in access to effective, culturally relevant cessation support among American Indian and Alaska Native (AI/AN) communities have contributed to poor cessation outcomes, and consequently, to smoking-related health inequities. OBJECTIVE Here we describe the protocol for a randomized clinical trial (RCT) that is testing the efficacy of a culturally adapted smoking cessation app (IndigeQuit) developed specifically to help AI/AN adults quit commercial cigarette smoking relative to a standard, non-tailored app (QuitGuide). METHODS To improve the relevance and acceptability of cessation support to AI/AN adults, IndigeQuit was developed through a cultural adaptation of iCanQuit, an evidence-based smartphone application grounded in acceptance and commitment therapy that teaches skills for accepting cravings to smoke. The cultural adaptation followed a community-based participatory research mixed methods approach with a Community Advisory Board (CAB) of AI/AN individuals. Cultural adaptations included the use of Native imagery, stories featuring AI/AN adults and elders emphasizing culture, spirituality, family, and community, and the important distinction between ceremonial and commercial tobacco. A total of 776 AI/AN adults who smoke and want to quit are being recruited nationwide and randomized to receive IndigeQuit or QuitGuide for 12 months. The primary aim of the RCT is to determine the efficacy of IndigeQuit vs QuitGuide for 30-day abstinence at 12 months. Secondary aims include abstinence at earlier timepoints, identifying mediators and moderators of treatment effects, and assessing engagement and satisfaction. Qualitative interviews with IndigeQuit participants and CAB members will inform the development of a subsequent guide to support the broad dissemination of IndigeQuit nationwide. RESULTS The National Institute of Cancer funded this study in 2024 (R01 CA284687, Principal Investigator, JBB). As of May 2026, 353 AI/AN adults had been enrolled in the trial. Enrollment is expected to be completed by November 2028. CONCLUSIONS The IndigeQuit app was designed to deliver evidence-based smoking cessation treatment that is culturally adapted to AI/AN and grounded in Acceptance and Commitment Therapy. If effective, this intervention could offer a more scalable and culturally relevant treatment to AI/AN communities nationwide, helping to reduce smoking-related health inequities. CLINICALTRIAL ClinicalTrials.gov Identifier, NCT06145763; https://clinicaltrials.gov/study/NCT06145763

  • Open Access

    Development of a Culturally Adapted Smartphone App (IndigeQuit) Designed to Help American Indian and Alaska Native People Quit Commercial Cigarettes: User-Centered Mixed Methods Study

    by Jonathan B Bricker, Margarita Santiago-Torres, Brianna M Sullivan, Kristin E Mull, Hershel W Clark, Camille A Fogel, Soo Bin Hwang, Alison R Keith, Chase Kornacki, Trivia Afraid Of Lightning-Craddock, et al.

    Background: Due to the colonization of tobacco plants by European settlers and the subsequent intensive marketing of commercial tobacco products to American Indian and Alaska Native (AI/AN) communities in the United States, commercial cigarette smoking accounts for half of all deaths among AI/AN people. Limited awareness, access to treatment, and the absence of culturally relevant, effective smoking cessation interventions contribute to these high death rates. Objective: This study aims to culturally adapt iCanQuit, a smartphone smoking cessation app proven efficacious for the general population, for AI/AN people. Methods: A user-centered and community-based participatory research (CBPR) mixed methods approach was applied to culturally adapt iCanQuit for AI/AN people in collaboration with a community advisory board (CAB) of AI/AN individuals using a 3-step process. Step 1 identified ways to culturally adapt the iCanQuit for AI/AN people through 1-on-1 qualitative interviews with 8 prior iCanQuit AI/AN participants. Step 2 involved developing prototypes of cultural refinements identified in step 1 through regular biweekly meetings of the CAB, research, and app development teams. The prototypes were then evaluated with a separate group of 4 prior iCanQuit AI/AN participants through 1-on-1 qualitative interviews. Step 3 involved beta testing the app through a 6-day diary study followed by 1-on-1 qualitative interviews with a nationally recruited group of 7 AI/AN adults who smoke commercial cigarettes. The development work associated with step 3 was further informed by the CAB and the research and app development teams. Results: Key findings identified 5 cultural refinements that informed subsequent app development and testing: (1) stories featuring AI/AN adults and elders emphasizing culture, spirituality, family, and community; (2) honoring the Earth as a motivator for cessation; (3) a guide character representative of AI/AN people; (4) clear distinction between ceremonial and commercial tobacco use; and (5) use of earth tones in visual design. In Step 3, all 7 (100%) diary study participants rated the beta version of the app as excellent or good/meets expectations (5/7, 71%, and 2/7, 29%, respectively) and that it felt made for them. They suggested 6 modifications which were incorporated into the final version of the app: (1) include vaping frequently asked questions, (2) feature motivation icons more prominently, (3) increase notification frequency, (4) track today’s cigarettes rather than yesterday’s, (5) allow users to update how much they spend per pack of cigarettes; and (6) rename the medications tool to reflect the inclusion of AI/AN traditional healing modalities. Conclusions: A user-centered and CBPR development process yielded IndigeQuit—one of the first known apps developed specifically to help AI/AN adults quit commercial cigarette smoking. Trial Registration: ClinicalTrials.gov NCT06145763; https://clinicaltrials.gov/ct2/show/NCT06145763


  • Open Access

    Development of a Culturally Adapted Smartphone App (IndigeQuit) Designed to Help American Indian and Alaska Native People Quit Commercial Cigarettes: User-Centered Mixed Methods Study (Preprint)

    by Jonathan B Bricker, Margarita Santiago-Torres, Brianna M Sullivan, Kristin E Mull, Hershel W Clark, Camille A Fogel, Soo Bin Hwang, Alison R Keith, Chase Kornacki, Trivia Afraid Of Lightning-Craddock, et al.

    BACKGROUND Due to the colonization of tobacco plants by European settlers and the subsequent intensive marketing of commercial tobacco products to American Indian and Alaska Native (AI/AN) communities in the United States, commercial cigarette smoking accounts for half of all deaths among AI/AN people. Limited awareness, access to treatment, and the absence of culturally relevant, effective smoking cessation interventions contribute to these high death rates. OBJECTIVE This study aims to culturally adapt iCanQuit, a smartphone smoking cessation app proven efficacious for the general population, for AI/AN people. METHODS A user-centered and community-based participatory research (CBPR) mixed methods approach was applied to culturally adapt iCanQuit for AI/AN people in collaboration with a community advisory board (CAB) of AI/AN individuals using a 3-step process. Step 1 identified ways to culturally adapt the iCanQuit for AI/AN people through 1-on-1 qualitative interviews with 8 prior iCanQuit AI/AN participants. Step 2 involved developing prototypes of cultural refinements identified in step 1 through regular biweekly meetings of the CAB, research, and app development teams. The prototypes were then evaluated with a separate group of 4 prior iCanQuit AI/AN participants through 1-on-1 qualitative interviews. Step 3 involved beta testing the app through a 6-day diary study followed by 1-on-1 qualitative interviews with a nationally recruited group of 7 AI/AN adults who smoke commercial cigarettes. The development work associated with step 3 was further informed by the CAB and the research and app development teams. RESULTS Key findings identified 5 cultural refinements that informed subsequent app development and testing: (1) stories featuring AI/AN adults and elders emphasizing culture, spirituality, family, and community; (2) honoring the Earth as a motivator for cessation; (3) a guide character representative of AI/AN people; (4) clear distinction between ceremonial and commercial tobacco use; and (5) use of earth tones in visual design. In Step 3, all 7 (100%) diary study participants rated the beta version of the app as excellent or good/meets expectations (5/7, 71%, and 2/7, 29%, respectively) and that it felt made for them. They suggested 6 modifications which were incorporated into the final version of the app: (1) include vaping frequently asked questions, (2) feature motivation icons more prominently, (3) increase notification frequency, (4) track today’s cigarettes rather than yesterday’s, (5) allow users to update how much they spend per pack of cigarettes; and (6) rename the medications tool to reflect the inclusion of AI/AN traditional healing modalities. CONCLUSIONS A user-centered and CBPR development process yielded IndigeQuit—one of the first known apps developed specifically to help AI/AN adults quit commercial cigarette smoking. CLINICALTRIAL ClinicalTrials.gov NCT06145763; https://clinicaltrials.gov/ct2/show/NCT06145763

  • Open Access

    Does living near a tobacco retailer impact the efficacy of smoking cessation treatments?: Analysis from a randomized trial

    by Margarita Santiago-Torres, Kristin E. Mull, Brianna M. Sullivan, Jonathan B. Bricker

  • Open Access

    Population-Level Dissemination of a Smoking Cessation Smartphone App: Quasi-Experimental Comparison of Values-Based Messages in Social Media Advertisements

    by Jonathan B Bricker, Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Ravi Mehrotra

    Background: Cigarette smoking is prevalent in many countries worldwide, especially in low- and middle-income countries (LMICs), presenting an urgent public health challenge. Disseminating freely available smoking cessation treatments that effectively decrease cigarette smoking globally is urgently needed. Objective: Identify the highest impact and most cost-effective values-based social media advertisements to disseminate our smoking cessation smartphone app, “iCanQuit”, among adults living in 7 major cities of India. Values represented in the advertisements included family, relationships, self-care, health, and self-control. Using a quasi-experimental design, we aimed to determine (1) which values-based advertisements had the highest smoking cessation app dissemination reach, as measured by click-through rate (CTR), app installs, and app usage metrics; and (2) which values-based message advertisements were more cost-effective as measured by cost-per-impression, cost-per-click, and cost-per-install. The study population included a selected media market of individuals living in 7 metro cities of India – Delhi, Mumbai, Kolkata, Chennai, Bengaluru, Hyderabad, and Pune – who were exposed to one of 6 social media advertisements from January 16 to May 5, 2024. Methods: The advertisement campaign design for each of the identified values, based on previous smoking cessation trial data, followed a collaborative iterative process. Advertisements ran sequentially for 16 weeks. Advertisement exposure and app usage data were objectively collected via Google’s Display & Video 360 advertisements campaign management and Firebase app development platforms. Advertisement exposure impact on app engagement was measured via several metrics, including click-through rate (CTR, ie, the likelihood of user clicks on an advertisement after seeing it), the number of app installs (ie, a user opening the app for the first time after downloading it), and the number of app sessions (ie, app usage). Cost efficiency was measured via cost per click and cost per install for each ad. Results: Overall, the CTR was 5%. The app was installed 5111 times. The average cost per click and cost per app install across all advertisements were US $ 0.006 and US $ 6.43, respectively. The advertisements with the lowest cost per install (range: US $4.83-US $5.16) and highest CTR (between 6% and 9%) focused on the values of family, health, and self-control. Advertisements focused on the values of relationships and self-care had modestly higher levels of engagement. Conclusions: Advertisements focusing on the values of family, health, and self-control had the highest potential reach at the lowest cost. Overall, these findings provide insights into the reach and cost-effectiveness of values-based messages in social media advertisements, guiding future outreach efforts for population-level dissemination of smoking cessation apps.


  • Open Access

    Evaluating the Impact of Pharmacotherapy in Augmenting Quit Rates Among Hispanic Adults in an App-Delivered Smoking Cessation Intervention: Secondary Analysis of a Randomized Controlled Trial

    by Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Ana Paula Cupertino, Ramzi G Salloum, Matthew Triplette, Michael J Zvolensky, Jonathan B Bricker

    Background: Hispanic adults receive less advice to quit smoking and use fewer evidence-based smoking cessation treatments compared to their non-Hispanic counterparts. Digital smoking cessation interventions, such as those delivered via smartphone apps, provide a feasible and within-reach treatment option for Hispanic adults who smoke and want to quit smoking. While the combination of pharmacotherapy and behavioral interventions are considered best practices for smoking cessation, its efficacy among Hispanic adults, especially alongside smartphone app–based interventions, is uncertain. Objective: This secondary analysis used data from a randomized controlled trial that compared the efficacy of 2 smoking cessation apps, iCanQuit (based on acceptance and commitment therapy) and QuitGuide (following US clinical practice guidelines), to explore the association between pharmacotherapy use and smoking cessation outcomes among the subsample of 173 Hispanic participants who reported on pharmacotherapy use. Given the randomized design, we first tested the potential interaction of pharmacotherapy use and intervention arm on 12-month cigarette smoking abstinence. We then examined whether the use of any pharmacotherapy (ie, nicotine replacement therapy [NRT], varenicline, or bupropion) and NRT alone augmented each app-based intervention efficacy. Methods: Participants reported using pharmacotherapy on their own during the 3-month follow-up and cigarette smoking abstinence at the 12-month follow-up via web-based surveys. These data were used (1) to test the interaction effect of using pharmacotherapy to aid smoking cessation and intervention arm (iCanQuit vs QuitGuide) on smoking cessation at 12 months and (2) to test whether the use of pharmacotherapy to aid smoking cessation augmented the efficacy of each intervention arm to help participants successfully quit smoking. Results: The subsample of Hispanic participants was recruited from 30 US states. They were on average 34.5 (SD 9.3) years of age, 50.9% (88/173) were female, and 56.1% (97/173) reported smoking at least 10 cigarettes daily. Approximately 22% (38/173) of participants reported using pharmacotherapy to aid smoking cessation at the 3-month follow-up, including NRT, varenicline, or bupropion, with no difference between intervention arms. There was an interaction between pharmacotherapy use and intervention arm that marginally influenced 12-month quit rates at 12 months (P for interaction=.053). In the iCanQuit arm, 12-month missing-as-smoking quit rates were 43.8% (7/16) for pharmacotherapy users versus 28.8% (19/16) for nonusers (odds ratio 2.21, 95% CI 0.66-7.48; P=.20). In the QuitGuide arm, quit rates were 9.1% (2/22) for pharmacotherapy users versus 21.7% (15/69) for nonusers (odds ratio 0.36, 95% CI 0.07-1.72; P=.20). Results were similar for the use of NRT only. Conclusions: Combining pharmacotherapy to aid smoking cessation with a smartphone app–based behavioral intervention that teaches acceptance of cravings to smoke (iCanQuit) shows promise in improving quit rates among Hispanic adults. However, this combined approach was not effective with the US clinical guideline–based app (QuitGuide). Trial Registration: ClinicalTrials.gov NCT02724462; https://clinicaltrials.gov/study/NCT02724462 International Registered Report Identifier (IRRID): RR2-10.1001/jamainternmed.2020.4055


  • Open Access

    Population-Level Dissemination of a Smoking Cessation Smartphone App: Comparison of Values-Based Messages in Social Media Advertisements (Preprint)

    by Jonathan B Bricker, Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Ravi Mehrotra

    BACKGROUND Cigarette smoking is prevalent in many countries worldwide, especially in low- and middle-income countries, presenting an urgent public health challenge. Disseminating freely available smoking cessation treatments that effectively decrease cigarette smoking globally are urgently needed. OBJECTIVE Identify the highest impact and most cost-effective values-based social media advertisements (ads) to disseminate our smoking cessation smartphone application (app), “iCanQuit”, among adults living in seven major cities of India. Values represented in the ads included family, relationships, self-care, health, and self-control. METHODS Ad exposure impact on app engagement was measured via several metrics, including click-through rate (CTR, i.e., the likelihood of user clicks on an ad after seeing it), the number of app installs (i.e., a user opening the app for the first time after downloading it), and the number of app sessions (i.e., app utilization). Cost efficiency was measured via cost per click and cost per install for each ad. RESULTS Overall, the CTR was 5%. The app was installed 5,111 times. The average cost per click and cost per app install across all ads were $0.006 and $6.43, respectively. The ads with the lowest cost per install (range: $4.83 to $5.16) and highest CTR (between 6% and 9%) focused on the values of family, health, and self-control. Ads focused on the values of relationships and self-care had modestly higher levels of engagement. CONCLUSIONS Ads focusing on the values of family, health, and self-control had the highest potential reach at the lowest cost. Overall, these findings provide insights into the reach and cost-effectiveness of values-based messages in social media advertisement, guiding future outreach efforts for population-level dissemination of smoking cessation apps. CLINICALTRIAL ClinicalTrials.gov Identifier, NCT02724462 INTERNATIONAL REGISTERED REPORT RR2-10.1001/jamainternmed.2020.4055

  • Open Access

    Evaluating the Impact of Pharmacotherapy in Augmenting Quit Rates Among Hispanic Adults in an App-Delivered Smoking Cessation Intervention: Secondary Analysis of a Randomized Controlled Trial (Preprint)

    by Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Ana Paula Cupertino, Ramzi G Salloum, Matthew Triplette, Michael J Zvolensky, Jonathan B Bricker

    BACKGROUND Hispanic adults receive less advice to quit smoking and use fewer evidence-based smoking cessation treatments compared to their non-Hispanic counterparts. Digital smoking cessation interventions, such as those delivered via smartphone apps, provide a feasible and within-reach treatment option for Hispanic adults who smoke and want to quit smoking. While the combination of pharmacotherapy and behavioral interventions are considered best practices for smoking cessation, its efficacy among Hispanic adults, especially alongside smartphone app–based interventions, is uncertain. OBJECTIVE This secondary analysis used data from a randomized controlled trial that compared the efficacy of 2 smoking cessation apps, iCanQuit (based on acceptance and commitment therapy) and QuitGuide (following US clinical practice guidelines), to explore the association between pharmacotherapy use and smoking cessation outcomes among the subsample of 173 Hispanic participants who reported on pharmacotherapy use. Given the randomized design, we first tested the potential interaction of pharmacotherapy use and intervention arm on 12-month cigarette smoking abstinence. We then examined whether the use of any pharmacotherapy (ie, nicotine replacement therapy [NRT], varenicline, or bupropion) and NRT alone augmented each app-based intervention efficacy. METHODS Participants reported using pharmacotherapy on their own during the 3-month follow-up and cigarette smoking abstinence at the 12-month follow-up via web-based surveys. These data were used (1) to test the interaction effect of using pharmacotherapy to aid smoking cessation and intervention arm (iCanQuit vs QuitGuide) on smoking cessation at 12 months and (2) to test whether the use of pharmacotherapy to aid smoking cessation augmented the efficacy of each intervention arm to help participants successfully quit smoking. RESULTS The subsample of Hispanic participants was recruited from 30 US states. They were on average 34.5 (SD 9.3) years of age, 50.9% (88/173) were female, and 56.1% (97/173) reported smoking at least 10 cigarettes daily. Approximately 22% (38/173) of participants reported using pharmacotherapy to aid smoking cessation at the 3-month follow-up, including NRT, varenicline, or bupropion, with no difference between intervention arms. There was an interaction between pharmacotherapy use and intervention arm that marginally influenced 12-month quit rates at 12 months (P for interaction=.053). In the iCanQuit arm, 12-month missing-as-smoking quit rates were 43.8% (7/16) for pharmacotherapy users versus 28.8% (19/16) for nonusers (odds ratio 2.21, 95% CI 0.66-7.48; P=.20). In the QuitGuide arm, quit rates were 9.1% (2/22) for pharmacotherapy users versus 21.7% (15/69) for nonusers (odds ratio 0.36, 95% CI 0.07-1.72; P=.20). Results were similar for the use of NRT only. CONCLUSIONS Combining pharmacotherapy to aid smoking cessation with a smartphone app–based behavioral intervention that teaches acceptance of cravings to smoke (iCanQuit) shows promise in improving quit rates among Hispanic adults. However, this combined approach was not effective with the US clinical guideline–based app (QuitGuide). CLINICALTRIAL ClinicalTrials.gov NCT02724462; https://clinicaltrials.gov/study/NCT02724462 INTERNATIONAL REGISTERED REPORT RR2-10.1001/jamainternmed.2020.4055